TAMPA, Fla. (WFLA) — Whenever you get bloodwork done, you probably don’t know what exactly you’re supposed to be looking at on the sheet (unless you’re a healthcare provider, that is). Glucose, sodium ...

LFTs are a panel of blood tests that help detect liver injury, cholestasis or synthetic dysfunction. Learn what each marker ...

Oral presentation to highlight 24-week efficacy and safety dataPoster to feature results of AI-based analyses of liver fibrosis ...

Altimmune (($ALT)) announced an update on their ongoing clinical study. Study Overview: The RESTORE TRIAL is a Phase 2 study conducted by ...

With lifestyle disorders and non-communicable diseases on the rise, many people routinely undergo Liver Function Tests (LFTs) ...

Altimmune Inc (NASDAQ:ALT) hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments for pemvidutide.

Altimmune Inc (NASDAQ:ALT) shares jumped 8.5% to $5.61 on Friday, ahead of next week’s presentation at the European Association for the Study of the Liver International Liver Congress 2025. The stock ...

Recently, the research team led by Prof. Hanyang Li at Harbin Engineering University has integrated functionalized liquid crystal (LC) microcavities with whispering-gallery-mode (WGM) laser technology ...

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC ...